Can a vaccine and a urine test tame HPV16?
NCT ID NCT07407569
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether the Gardasil 9 vaccine can reduce the infectivity of HPV16 virus in women who already have the infection. About 50 women aged 18-45 will receive two doses of the vaccine, and researchers will use urine samples to measure virus activity and immune responses. The goal is to see if the vaccine can lower the virus's ability to infect cells and to develop a non-invasive way to monitor this.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gardasil 9 vaccine
- What this could lead to
- If successful, this could show that the Gardasil 9 vaccine reduces HPV16 infectivity and help develop a simple urine test to monitor vaccine effects.
- What could go wrong
- This is a small, early-phase study with only 50 women, so results may not apply to everyone. The vaccine is used off-label, and the main goal is to test a new urine-based method, not to prove clinical benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS INFECTION TYPE 16 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Antwerp University Hospital
RECRUITINGAntwerp, Wilrijk, 2650, Belgium
-
University Hospital Ghent
RECRUITINGGhent, 9000, Belgium
-
University Hospital Leuven
RECRUITINGLeuven, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.